Cardio-oncology is the subspecialty concerned with monitoring and managing cardiotoxicity arising from cancer therapies, distinguishing mechanistically reversible dysfunction (e.g., HER2-targeted antibody therapy, which transiently stuns myocardium without cell death) from irreversible, dose-dependent cardiomyocyte injury (e.g., anthracyclines, which cause cardiac myocyte death). Risk stratification incorporates cumulative drug dose, baseline cardiovascular comorbidities, and surveillance modalities—ejection fraction imaging and cardiac biomarkers—to detect subclinical toxicity before irreversible decline, while a separate immune-mediated mechanism (checkpoint-inhibitor-induced myocarditis) requires early high-dose steroid intervention due to its high case-fatality rate.
Cardio-oncology is the subspecialty concerned with monitoring and managing cardiotoxicity arising from cancer therapies, distinguishing mechanistically reversible dysfunction (e.g., HER2-targeted ant…